Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Chief Medical Officer | March 25, 2026 | March 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date March 25, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2036-03-24 | Direct | 72,555 |
Reported balance
After 2026-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-25 · Grant · Acquired 72,555 · Balance 72,555 F1: (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2026 Filed Mar 27, 2026 16:10 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 72,555 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0002052749-26-000003 · ownership.xml · derivative · entry 1 Maltzman Julia D. · CIK 0002052749 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,555 Underlying: Common Stock · 72,555 shares Expires 2036-03-24 F1 · derivative.exercise_date: (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:40 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0000950170-25-013596 · ownership.xml · derivative · entry 1 Maltzman Julia D. · CIK 0002052749 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2035-01-30 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on December 7, 2025, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.